Thus, the analysis of NF-κB/IκB expression was proposed as companion predictive marker for a potential combinatorial therapy pharmacologically targeting NF-κB in EGFRM+ NSCLC [290]. This evidence concerns the gene NFKB1 and non-small cell lung carcinoma.